Tags

Type your tag names separated by a space and hit enter

Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19.
Transl Lung Cancer Res. 2020 Apr; 9(2):337-347.TL

Abstract

Since December, 2019, a 2019 novel coronavirus disease (COVID-19) infected by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) emerged in Wuhan, Hubei province, and the epidemic situation has continued to spread globally. The epidemic spread of COVID-19 has brought great challenges to the clinical practice of thoracic oncology. Outpatient clinics need to strengthen the differential diagnosis of initial symptoms, pulmonary ground-glass opacity (GGO), consolidation, interstitial and/or interlobular septal thickening, and crazy paving appearance. In the routine of oncology, the differential diagnosis of adverse events from COVID-19 is also significant, including radiation pneumonitis, checkpoint inhibitor pneumonitis (CIP), neutropenic fever, and so on. During the epidemic, indications of transbronchial biopsy (TBB) and CT-guided percutaneous thoracic biopsy are strictly controlled. For patients who are planning to undergo biopsy operation, screening to exclude the possibility of COVID-19 should be carried out. For confirmed or suspected patients, three-level protection should be performed during the operation. Disinfection and isolation measures should be strictly carried out during the operation. At last, more attention to the protection of cancer patients and give priority to the treatment of infected cancer patients.

Authors+Show Affiliations

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. Tongji University, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32420073

Citation

Guo, Haoyue, et al. "Challenges and Countermeasures of Thoracic Oncology in the Epidemic of COVID-19." Translational Lung Cancer Research, vol. 9, no. 2, 2020, pp. 337-347.
Guo H, Chen X, Su C, et al. Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19. Transl Lung Cancer Res. 2020;9(2):337-347.
Guo, H., Chen, X., Su, C., Liu, Y., Wang, H., Sun, C., Chen, P., Jiang, M., Xu, Y., Wu, S., Jia, K., Zhao, S., Li, W., Chen, B., Wang, L., Yu, J., Xiong, A., Gao, G., Wu, F., ... Zhou, C. (2020). Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19. Translational Lung Cancer Research, 9(2), 337-347. https://doi.org/10.21037/tlcr.2020.02.10
Guo H, et al. Challenges and Countermeasures of Thoracic Oncology in the Epidemic of COVID-19. Transl Lung Cancer Res. 2020;9(2):337-347. PubMed PMID: 32420073.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19. AU - Guo,Haoyue, AU - Chen,Xiaoxia, AU - Su,Chunxia, AU - Liu,Yu, AU - Wang,Hao, AU - Sun,Chenglong, AU - Chen,Peixin, AU - Jiang,Minlin, AU - Xu,Yi, AU - Wu,Shengyu, AU - Jia,Keyi, AU - Zhao,Sha, AU - Li,Wei, AU - Chen,Bin, AU - Wang,Lei, AU - Yu,Jia, AU - Xiong,Anwen, AU - Gao,Guanghui, AU - Wu,Fengying, AU - Li,Jiayu, AU - Ye,Lingyun, AU - Bo,Bing, AU - Chen,Shen, AU - Ren,Shengxiang, AU - He,Yayi, AU - Zhou,Caicun, PY - 2020/5/19/entrez PY - 2020/5/19/pubmed PY - 2020/5/19/medline KW - 2019 novel coronavirus disease (COVID-19) KW - severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) KW - thoracic oncology SP - 337 EP - 347 JF - Translational lung cancer research JO - Transl Lung Cancer Res VL - 9 IS - 2 N2 - Since December, 2019, a 2019 novel coronavirus disease (COVID-19) infected by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) emerged in Wuhan, Hubei province, and the epidemic situation has continued to spread globally. The epidemic spread of COVID-19 has brought great challenges to the clinical practice of thoracic oncology. Outpatient clinics need to strengthen the differential diagnosis of initial symptoms, pulmonary ground-glass opacity (GGO), consolidation, interstitial and/or interlobular septal thickening, and crazy paving appearance. In the routine of oncology, the differential diagnosis of adverse events from COVID-19 is also significant, including radiation pneumonitis, checkpoint inhibitor pneumonitis (CIP), neutropenic fever, and so on. During the epidemic, indications of transbronchial biopsy (TBB) and CT-guided percutaneous thoracic biopsy are strictly controlled. For patients who are planning to undergo biopsy operation, screening to exclude the possibility of COVID-19 should be carried out. For confirmed or suspected patients, three-level protection should be performed during the operation. Disinfection and isolation measures should be strictly carried out during the operation. At last, more attention to the protection of cancer patients and give priority to the treatment of infected cancer patients. SN - 2218-6751 UR - https://www.unboundmedicine.com/medline/citation/32420073/Challenges_and_countermeasures_of_thoracic_oncology_in_the_epidemic_of_COVID-19 L2 - https://doi.org/10.21037/tlcr.2020.02.10 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.